drugset
drugset / Trial / NCT03772665

Safety and Efficacy of Emixustat in Stargardt Disease

NCT03772665 ↗

Phase 3 Completed 194 enrolled Kubota Vision Inc. Food and Drug Administration (FDA) · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA OOPD

Timeline

Start
2019-01-07
Primary completion
2022-06-13
Completion
2022-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Emixustat Small molecule 10 mg Oral

Indications

Stargardt disease